Status:
UNKNOWN
Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborating Sponsors:
Ministry of Science and Technology, Taiwan
Conditions:
Amphetamine Addiction
Pharmacotherapy
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The investigators will conducted a randomized double-blind placebo-controlled study to investigate the treatment outcomes of add-on low dose dextromethorphan (DM), memantine (MM), or dextromethorphan ...
Detailed Description
The investigators will conducted a randomized double-blind placebo-controlled study to investigate the treatment outcomes of add-on low dose dextromethorphan (60mg/day, DM), memantine (5 mg/day, MM), ...
Eligibility Criteria
Inclusion
- Signed informed consent by patient or legal representative.
- Male or female patient aged ≧20 and ≦65 years.
- A diagnosis of ATSUD according to DSM criteria made by a specialist in psychiatry.
- Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.
Exclusion
- The presence of any of the following will exclude a patient from study enrollment:
- Women of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study.
- Females who are pregnant or lactation.
- Other major Axis-I DSM-IV diagnosis other than ATSUD, except for tobacco use disorder, ATS induced mood or psychotic disorders.
- Current evidence of an uncontrolled and/or clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.
- History of allergy or intolerable side effects of DM or MM.
- Suicidal attempts or risks during screen or study period.
- Presence of active infectious or autoimmune disease.
Key Trial Info
Start Date :
August 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04687566
Start Date
August 11 2020
End Date
July 31 2024
Last Update
December 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University
Tainan, Taiwan, 70428